Given the evidence that targeting TCTP with DHA changed non-T cell-inflamed (TIL−) tumors into T cell-inflamed (TIL+) tumors (Fig. 7), treatment of PD-L1+/TIL- or PD-L1+/TCTP+ patients with DHA may convert the tumor type to TIL+, thereby providing clinical benefits to ICB therapy. This evidence concerns the gene CD274 and neoplasm.